SWX:IDIABiotechs
Does Idorsia’s Latin America QUVIVIQ Deal and Lucerastat Data Change The Bull Case For Idorsia (SWX:IDIA)?
Idorsia has recently announced an exclusive license and supply agreement with EMS S.A. to register and commercialize its insomnia medicine QUVIVIQ (daridorexant) across Latin America, while also presenting long-term data on lucerastat suggesting disease-modifying potential in Fabry disease at the WORLDSymposium.
Together, these developments highlight Idorsia’s push to expand QUVIVIQ into new geographies and progress lucerastat toward a defined regulatory path in a rare disease setting.
We’ll...